The first in vivo trial of the use of interferon-beta in a mouse model of the group of fatal diseases known as spinocerebellar ataxia has shown that its use can significantly improve their physical condition and control symptoms. Researchers in France and the US believe that their results show that a clinical trial in humans is merited.
Fuente : http://www.eurekalert.org/pub_releases/2013-06/eso...
Fuente : http://www.eurekalert.org/pub_releases/2013-06/eso...



Tendencias Científicas
La prevención del VIH no llega a las jóvenes sudafricanas

CIENCIA ON LINE